FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2927614515> ?p ?o ?g. }

• W2927614515 endingPage "82" @default.
• W2927614515 startingPage "73" @default.
• W2927614515 abstract "Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis evaluated tofacitinib persistence in patients with RA in long-term extension (LTE) studies up to 9.5 years.Data were pooled from two LTE studies: ORAL Sequel (NCT00413699) and Study A3921041 (NCT00661661). Patients received tofacitinib 5 or 10 mg twice daily (BID), as monotherapy or with background conventional synthetic disease-modifying antirheumatic drugs. Kaplan-Meier estimates for tofacitinib drug survival and reasons for discontinuation were evaluated. Baseline factors were analyzed as predictors of persistence.In 4967 tofacitinib-treated patients entering LTE studies, mean (maximum) treatment duration was 3.5 (9.4) years. Median drug survival (95% confidence interval) was 4.9 (4.7, 5.1) years. Estimated 2- and 5-year drug survival rates were 75.5% and 49.4%, respectively. Median drug survival was similar between the tofacitinib 5 and 10 mg BID groups, and slightly higher for patients receiving tofacitinib monotherapy versus combination therapy. Overall, 50.7% of patients discontinued tofacitinib; of these, 47.2% were due to adverse events and 7.1% for lack/loss of efficacy. An increased risk of discontinuation was associated with baseline diabetes, hypertension, negative anticyclic citrullinated peptide (anti-CCP), negative rheumatoid factor (RF), and inadequate response to tumor necrosis factor inhibitors (TNFi-IR).Median drug survival of tofacitinib-treated patients participating in LTE studies was approximately 5 years and was similar for tofacitinib dosed at 5 and 10 mg BID. Reduced drug survival was associated with negative anti-CCP/RF status, TNFi-IR, and certain comorbidities. These data support tofacitinib use for long-term management of RA." @default.
• W2927614515 created "2019-04-11" @default.
• W2927614515 creator A5000141404 @default.
• W2927614515 creator A5009475149 @default.
• W2927614515 creator A5023213876 @default.
• W2927614515 creator A5025867925 @default.
• W2927614515 creator A5028283706 @default.
• W2927614515 creator A5030150540 @default.
• W2927614515 creator A5042742781 @default.
• W2927614515 creator A5080646462 @default.
• W2927614515 creator A5090182951 @default.
• W2927614515 date "2019-03-28" @default.
• W2927614515 modified "2023-10-16" @default.
• W2927614515 title "Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years" @default.
• W2927614515 cites W1561772993 @default.
• W2927614515 cites W1572054273 @default.
• W2927614515 cites W1974321634 @default.
• W2927614515 cites W1990105300 @default.
• W2927614515 cites W1997568521 @default.
• W2927614515 cites W2014330392 @default.
• W2927614515 cites W2035320881 @default.
• W2927614515 cites W2038992287 @default.
• W2927614515 cites W2046744512 @default.
• W2927614515 cites W2069302785 @default.
• W2927614515 cites W2069871920 @default.
• W2927614515 cites W2097302763 @default.
• W2927614515 cites W209787019 @default.
• W2927614515 cites W2101217991 @default.
• W2927614515 cites W2104861305 @default.
• W2927614515 cites W2106962952 @default.
• W2927614515 cites W2129603347 @default.
• W2927614515 cites W2129948300 @default.
• W2927614515 cites W2138609584 @default.
• W2927614515 cites W2147681024 @default.
• W2927614515 cites W2149065814 @default.
• W2927614515 cites W2149447280 @default.
• W2927614515 cites W2152348310 @default.
• W2927614515 cites W2153124348 @default.
• W2927614515 cites W2153414586 @default.
• W2927614515 cites W2156140442 @default.
• W2927614515 cites W2164858045 @default.
• W2927614515 cites W2254470680 @default.
• W2927614515 cites W2265836205 @default.
• W2927614515 cites W2265946565 @default.
• W2927614515 cites W2344086033 @default.
• W2927614515 cites W2414968273 @default.
• W2927614515 cites W2471354035 @default.
• W2927614515 cites W2507874134 @default.
• W2927614515 cites W2547564737 @default.
• W2927614515 cites W2560815198 @default.
• W2927614515 cites W2584430503 @default.
• W2927614515 cites W2604128221 @default.
• W2927614515 cites W2617567494 @default.
• W2927614515 cites W2782539460 @default.
• W2927614515 cites W2793340325 @default.
• W2927614515 doi "https://doi.org/10.1002/acr2.1010" @default.
• W2927614515 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6857988" @default.
• W2927614515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31777783" @default.
• W2927614515 hasPublicationYear "2019" @default.
• W2927614515 type Work @default.
• W2927614515 sameAs 2927614515 @default.
• W2927614515 citedByCount "18" @default.
• W2927614515 countsByYear W29276145152019 @default.
• W2927614515 countsByYear W29276145152020 @default.
• W2927614515 countsByYear W29276145152021 @default.
• W2927614515 countsByYear W29276145152022 @default.
• W2927614515 countsByYear W29276145152023 @default.
• W2927614515 crossrefType "journal-article" @default.
• W2927614515 hasAuthorship W2927614515A5000141404 @default.
• W2927614515 hasAuthorship W2927614515A5009475149 @default.
• W2927614515 hasAuthorship W2927614515A5023213876 @default.
• W2927614515 hasAuthorship W2927614515A5025867925 @default.
• W2927614515 hasAuthorship W2927614515A5028283706 @default.
• W2927614515 hasAuthorship W2927614515A5030150540 @default.
• W2927614515 hasAuthorship W2927614515A5042742781 @default.
• W2927614515 hasAuthorship W2927614515A5080646462 @default.
• W2927614515 hasAuthorship W2927614515A5090182951 @default.
• W2927614515 hasBestOaLocation W29276145151 @default.
• W2927614515 hasConcept C126322002 @default.
• W2927614515 hasConcept C141071460 @default.
• W2927614515 hasConcept C197934379 @default.
• W2927614515 hasConcept C2776233030 @default.
• W2927614515 hasConcept C2777575956 @default.
• W2927614515 hasConcept C2778715236 @default.
• W2927614515 hasConcept C2778886723 @default.
• W2927614515 hasConcept C71924100 @default.
• W2927614515 hasConcept C90924648 @default.
• W2927614515 hasConceptScore W2927614515C126322002 @default.
• W2927614515 hasConceptScore W2927614515C141071460 @default.
• W2927614515 hasConceptScore W2927614515C197934379 @default.
• W2927614515 hasConceptScore W2927614515C2776233030 @default.
• W2927614515 hasConceptScore W2927614515C2777575956 @default.
• W2927614515 hasConceptScore W2927614515C2778715236 @default.
• W2927614515 hasConceptScore W2927614515C2778886723 @default.
• W2927614515 hasConceptScore W2927614515C71924100 @default.
• W2927614515 hasConceptScore W2927614515C90924648 @default.
• W2927614515 hasIssue "2" @default.
• W2927614515 hasLocation W29276145151 @default.

• next